2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN. Post author:alarpharm Post published:13 . 5 . 2022 Post category:Media releases You Might Also Like 2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021 2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 8 . 6 . 2021 2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI) 13 . 8 . 2020 2021/08/03 ALA-1000 Receive notice of patent allowance from Japan Patent Office (JPO), Application No. 特願2019-535434. 9 . 8 . 2021 2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021
2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 8 . 6 . 2021
2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI) 13 . 8 . 2020
2021/08/03 ALA-1000 Receive notice of patent allowance from Japan Patent Office (JPO), Application No. 特願2019-535434. 9 . 8 . 2021
2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021
